According to the Pharmaceutical Benefits Assessment Committee (PBAC) November 2023 agenda published last week, the meeting will be jammed with biopharma applications for reimbursement. PBAC will consider the following applications for PBS listing additions or amendments at its November 2023 meeting:
| New listing applications: | Amendment Applications |
| 1. Organon’s Hadlima® (adalimumab) biosimilar to AbbVie’s Humira® | 1. Sanofi-Aventis’ Libtayo® (cemiplimab) |
| 2. GSK’s Jemperli® (dostarlimab) | 2. BMS’s Opdivo® (nivolumab) |
| 3. Vertex’s Kalydeco® (ivacaftor) | 3. Merck’s Keytruda® (pembrolizumab) |
| 4. GSK’s Menveo® (meningococcal vaccine) | 4. AbbVie’s Skyrizi® (risankizumab) |
| 5. Pfizer’s Prevenar 20® (pneumococcal conjugate vaccine) | 5. Novartis’ Cosentyx® (secukinumab) |
| 6. Generic Health’s Teriparatide Lupin® (teriparatide) biosimilar to Eli Lily’s Forteo® | |
| 7. Gedeon Richter’s Terrosa® (teriparatide) biosimilar to Eli Lily’s Forteo® | |
| 8. Beigene’s Tevimbra® (tiselizumab) | |
| 9. AstraZeneca’s Enhertu® (trastuzumab deruxtecan) biosimilar to Genentech’s Herceptin® |
In addition, a number of PBAC recommendations not accepted by applicants are set for review, including relating to Alphapharm’s Hulio® (adalimumab, biosimilar to AbbVie’s Humira®), Pfizer’s Zirabev® (bevacizumab, biosimilar to Genentech’s Avastin®) and Alphapharm’s Rymti® (etanercept) biosimilar to Amgen’s Enbrel®.
On 1 March 2023, the November 2022 PBAC outcomes were announced, with three biologics listed, including Sanofi-Aventis’ dupilumab (Dupixent®) autoinjectors in two new forms, Merck’s pembrolizumab (Keytruda®) and AbbVie’s risankizumab (Skyrizi®).